The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?

Published:December 17, 2022DOI:


      • Cannabis might alter tumour's microenvironment and, hence, reduce the immune checkpoint inhibitors efficacy.
      • We investigate this theory in murine models and real-world data.
      • We found no determinantal effect of this combination in clinic or laboratory.
      • This conclusion has a great reassuring impact on our patients having non-small cell lung cancer.



      The use of medical cannabis has rapidly increased among cancer patients worldwide. Cannabis is often administered concomitantly with cancer medications, including immune checkpoint inhibitors (ICIs). As the cannabinoid receptors are abundantly expressed and modulate immune cells, it has been hypothesised that cannabis may attenuate the activity of ICIs. We aimed to assess the effect of cannabis on ICIs' efficiency in patients having non-small cell lung cancer (NSCLC).


      The murine model of CT26 tumour-bearing mice treated with an anti-PD-1 antibody and Δ9-tetrahydrocannabinol (THC) was used to evaluate the interaction between THC and ICIs in vivo.
      Correlation between use of medical cannabis and clinical outcome was evaluated in a cohort of 201 consecutive metastatic NSCLC patients treated with monotherapy pembrolizumab as a first-line treatment.


      Median overall survival (OS) of the mice receiving a control vehicle, THC, anti-PD-1 antibody or their combination was 21, 24, 31 and 54 days, respectively (p < 0.05 for the combination treatment compared to a control vehicle), indicating that THC did not reduce the efficacy of anti-PD-1 therapy.
      Of 201 NSCLC patients treated with first-line monotherapy pembrolizumab for metastatic disease, 102 (50.7%) patients received licence for cannabis within the first month of treatment. Cannabis-treated patients were younger compared to the cannabis naïve patients (median age 68 versus 74, p = 0.003), with female predominance (62, 60.8% versus 34, 34.3%, p = 0.002) and with more prevailing brain metastasis (15.7% versus 5%, p = 0.013). Similar distribution of histology, smoking status, ECOG (Eastern Cooperative Oncology Group) and programmed death-ligand 1 expression was noted between the groups. Liver metastases were marginally significant (19.6% versus 10.1%, p = 0.058). The most common indication for cannabis was pain (71%) followed by loss of appetite (34.3%). Time to tumour progression was similar for cannabis-naive and cannabis-treated patients (6.1 versus 5.6 months, respectively, 95% confidence interval, 0.82 to 1.38, p = 0.386), while OS was numerically higher in the cannabis-naive group (54.9 versus 23.6 months) but did not reach statistical significance (95% confidence interval 0.99 to 2.51, p = 0.08). In multivariate analyses, we did not identify cannabis use as an independent predictor factor for mortality.


      Preclinical and clinical data suggest no deleterious effect of cannabis on the activity of pembrolizumab as first-line monotherapy for advanced NSCLC. The differences in OS can most likely be attributed to higher disease burden and more symptomatic disease in the cannabis-treated group. These data provide reassurance regarding the absence of a deleterious effect of cannabis in this clinical setting.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cyr C.
        • Arboleda M.F.
        • Aggarwal S.K.
        • et al.
        Cannabis in palliative care: current challenges and practical recommendations.
        Ann Palliat Med. 2018;
        • Panozzo S.
        • Le B.
        • Collins A.
        • et al.
        Who is asking about medicinal cannabis in palliative care?.
        Intern Med J. 2020;
        • Bar-Lev Schleider L.
        • Mechoulam R.
        • Lederman V.
        • et al.
        Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer.
        Eur J Intern Med. 2018;
        • Kleckner A.S.
        • Kleckner I.R.
        • Kamen C.S.
        • et al.
        Opportunities for cannabis in supportive care in cancer.
        Ther Adv Med Oncol. 2019;
        • Häuser W.
        • Welsch P.
        • Klose P.
        • Radbruch L.
        • Fitzcharles M.A.
        Efficacy, tolerability and safety of cannabis-based medicines for cancer pain: a systematic review with meta-analysis of randomised controlled trials.
        Schmerz. 2019;
        • Okusanya B.O.
        • Asaolu I.O.
        • Ehiri J.E.
        • Kimaru L.J.
        • Okechukwu A.
        • Rosales C.
        Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review.
        Syst Rev. 2020;
        • Blake A.
        • Wan B.A.
        • Malek L.
        • et al.
        A selective review of medical cannabis in cancer pain management.
        Ann Palliat Med. 2017;
        • Machado Rocha F.C.
        • Stéfano S.C.
        • De Cássia Haiek R.
        • Rosa Oliveira L.M.Q.
        • Da Silveira D.X.
        Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis.
        Eur J Cancer Care. 2008;
        • Weiss M.C.
        • Hibbs J.E.
        • Buckley M.E.
        • et al.
        A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment.
        Cancer. 2022;
        • Waissengrin B.
        • Mirelman D.
        • Pelles S.
        • et al.
        Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis.
        Ther Adv Med Oncol. 2021;
        • Sznitman S.R.
        Trends in medical cannabis licensure, Israel, 2013–2018.
        Drug Alcohol Rev. 2020;
        • Waissengrin B.
        • Urban D.
        • Leshem Y.
        • Garty M.
        • Wolf I.
        Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience.
        J Pain Symptom Manag. 2015;
        • Isralowitz R.
        • Reznik A.
        • Zolotov Y.
        • et al.
        Toward medical cannabis education in Israel.
        Complement Ther Med. 2021;
        • Mirelman D.
        • Waissengrin B.
        • Goldway N.
        • Sharon H.
        • Brill S.
        • Wolf I.
        Use of medical cannabis: perceptions of Israeli oncologists.
        Lancet Oncol. 2019;
        • Aizpurua-Olaizola O.
        • Soydaner U.
        • Öztürk E.
        • et al.
        Evolution of the cannabinoid and terpene content during the growth of Cannabis sativa plants from different chemotypes.
        J Nat Prod. 2016;
        • Hanuš L.O.
        • Meyer S.M.
        • Muñoz E.
        • Taglialatela-Scafati O.
        • Appendino G.
        Phytocannabinoids: a unified critical inventory.
        Nat Prod Rep. 2016;
        • Berdyshev E.V.
        Cannabinoid receptors and the regulation of immune response.
        Chem Phys Lipids. 2000;
        • Turcotte C.
        • Blanchet M.R.
        • Laviolette M.
        • Flamand N.
        The CB2 receptor and its role as a regulator of inflammation.
        Cell Mol Life Sci. 2016;
        • Bouchard J.
        • Truong J.
        • Bouchard K.
        • et al.
        Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease.
        J Neurosci. 2012;
        • Braile M.
        • Cristinziano L.
        • Marcella S.
        • et al.
        LPS-mediated neutrophil VEGF-A release is modulated by cannabinoid receptor activation.
        J Leukoc Biol. 2021;
        • Reck M.
        • Rodríguez-Abreu D.
        • Robinson A.G.
        • et al.
        Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer.
        N Engl J Med. 2016;
        • Mok T.S.K.
        • Wu Y.L.
        • Kudaba I.
        • et al.
        Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
        Lancet. 2019;
        • Gandhi L.
        • Rodríguez-Abreu D.
        • Gadgeel S.
        • et al.
        Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer.
        N Engl J Med. 2018;
        • Paz-Ares L.
        • Luft A.
        • Vicente D.
        • et al.
        Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer.
        N Engl J Med. 2018;
        • Paz-Ares L.
        • Ciuleanu T.E.
        • Cobo M.
        • et al.
        First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021;
        • Taha T.
        • Meiri D.
        • Talhamy S.
        • Wollner M.
        • Peer A.
        • Bar-Sela G.
        Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies.
        Oncologist. 2019;
        • Bar-Sela G.
        • Cohen I.
        • Campisi-Pinto S.
        • et al.
        Cannabis consumption used by cancer patients during immunotherapy correlates with poor clinical outcome.
        Cancers. 2020;
        • Leshem Y.
        • O'Brien J.
        • Liu X.
        • et al.
        Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anticancer immunity.
        Cancer Immunol Res. 2017;
        • Leshem Y.
        • King E.M.
        • Mazor R.
        • Reiter Y.
        • Pastan I.
        SS1P immunotoxin induces markers of immunogenic cell death and enhances the effect of the CTLA-4 blockade in AE17M mouse mesothelioma tumors.
        Toxins. 2018;
        • Mosely S.I.S.
        • Prime J.E.
        • Sainson R.C.A.
        • et al.
        Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery.
        Cancer Immunol Res. 2017; 5: 29-41
        • Berman P.
        • Futoran K.
        • Lewitus G.M.
        • et al.
        A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis.
        Sci Rep. 2018;
        • Bessede A.
        • Marabelle A.
        • Guégan J.P.
        • et al.
        Impact of acetaminophen on the efficacy of immunotherapy in cancer patients.
        Ann Oncol. 2022;
        • McKallip R.J.
        • Nagarkatti M.
        • Nagarkatti P.S.
        Δ-9-Tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response.
        J Immunol. 2005; 174: 3281-3289
        • Zhu L.X.
        • Sharma S.
        • Stolina M.
        • et al.
        Δ-9-Tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
        J Immunol. 2000;
        • Fabritius M.
        • Chtioui H.
        • Battistella G.
        • et al.
        Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.
        Anal Bioanal Chem. 2013;
        • Ohlsson A.
        • Lindgren J.-E.
        • Wahlen A.
        • Agurell S.
        • Hollister L.E.
        • Gillespie H.K.
        Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking.
        Clin Pharmacol Ther. 1980;
        • Huestis M.A.
        • Henningfield J.E.
        • Cone E.J.
        Blood cannabinoids. i. absorption of thc and formation of 11-oh-thc and thccooh during and after smoking marijuana.
        J Anal Toxicol. 1992;
        • Guggisberg J.
        • Schumacher M.
        • Gilmore G.
        • Zylla D.M.
        Cannabis as an anticancer agent: a review of clinical data and assessment of case reports.
        Cannabis Cannabinoid Res. 2022;
        • Malhotra P.
        • Casari I.
        • Falasca M.
        Therapeutic potential of cannabinoids in combination cancer therapy.
        Adv Biol Regul. 2021;
        • Munson A.E.
        • Harris L.S.
        • Friedman M.A.
        • Dewey W.L.
        • Carchman R.A.
        Antineoplastic activity of cannabinoids2.
        J Natl Cancer Inst. 1975; 55: 597-602
        • Mokoena D.R.
        • George B.P.
        • Abrahamse H.
        Enhancing breast cancer treatment using a combination of cannabidiol and gold nanoparticles for photodynamic therapy.
        Int J Mol Sci. 2019;
        • Misri S.
        • Kaul K.
        • Mishra S.
        • et al.
        Cannabidiol inhibits tumorigenesis in cisplatin-resistant non-small cell lung cancer via TRPV2.
        Cancers. 2022;
        • Preet A.
        • Qamri Z.
        • Nasser M.W.
        • et al.
        Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.
        Cancer Prev Res. 2011;
        • Namdar D.
        • Koltai H.
        Medical cannabis for the treatment of inflammation.
        Nat Prod Commun. 2018; 131934578X1801300
        • Kenyon J.
        • Liu W.
        • Dalgleish A.
        Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol.
        Anticancer Res. 2018;
        • Kumar R.
        • Gupta N.
        A case of bronchial asthma and allergic rhinitis exacerbated during Cannabis pollination and subsequently controlled by subcutaneous immunotherapy.
        Indian J Allergy Asthma Immunol. 2013; 27: 143
        • Freimuth N.
        • Ramer R.
        • Hinz B.
        Antitumorigenic effects of cannabinoids beyond apoptosis.
        J Pharmacol Exp Ther. 2010; 332: 336-344
        • Afrin F.
        • Chi M.
        • Eamens A.L.
        • et al.
        Can hemp help? Low-THC cannabis and non-THC cannabinoids for the treatment of cancer.
        Cancers. 2020;
        • Biedny A.
        • Szpunar S.
        • Abdalla A.
        • Kafri Z.
        • Hadid T.H.
        The effect of concomitant cannabinoids during immune checkpoint inhibitor treatment of advanced stage malignancy.
        J Clin Orthod. 2020; 38: e15064
        • Brahmer J.R.
        • Rodriguez-Abreu D.
        • Robinson A.G.
        • et al.
        LBA51 KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%.
        Ann Oncol. 2020;